Paulus Kirchhof: Anticoagulation in Patients with a Single CHADS-VA Risk Factor
Paulus Kirchhof, Professor of Cardiovascular Medicine at the University of Birmingham, Professor of Medicine (Cardiology) and Director of the Department of Cardiology at the University Medical Center Hamburg-Eppendorf, shared a post on LinkedIn about his recent article, published in NEJM, adding:
“Anticoagulation in patients with a single CHADS-VA risk factor.
SINGLE-AF is an important trial that will inform clinical decisions.
The full paper is now available at the NEJM.
Many congratulations to all who realised SINGLE AF!
You can read my thoughts on SINGLE AF and on the use of anticoagulants in patients with atrial fibrillation and a single CHADS-VA risk factor here.
What is your take on anticoagulation in patients with atrial fibrillation and a single CHADS-VA risk factor?”
Title: Anticoagulation for Atrial Fibrillation with a Single Risk Factor for Stroke
Author: Paulus Kirchhof
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 29, 2026, 15:06Laurent Arnaud: Rare SLE Manifestations Demand More Than Rare Attention – Insights from The Lancet Rheumatology
-
Aug 29, 2026, 14:55Marco Vitolo: The Changing Landscape of Sex Differences in AF-Related Stroke
-
Aug 29, 2026, 14:54Hiteshi K.C. Chauhan: Should Patients with AF and Intermediate Stroke Risk Receive Anticoagulation?
-
Aug 29, 2026, 14:39C. Michael Gibson: SINGLE-AF Trial Supports DOAC Use in Intermediate-Risk Atrial Fibrillation
-
Aug 29, 2026, 14:07Vincent Rizzo: Beta Blocker Choice May Impact Portal Vein Thrombosis and Survival in Cirrhosis
-
Aug 29, 2026, 14:04Günalp Uzun: DGTI 2026 New Insights in Platelet Immunology and Hemostasis
-
Aug 29, 2026, 13:59Eleftheria Hatzimichael: ASH 2026 Guidelines for Primary ITP What Is Changing
-
Aug 29, 2026, 11:03Richard Davis: Navigating Acute PE – ESC vs. the New AHA/ACC Guidelines
-
Aug 29, 2026, 10:57Bartosz Hudzik: First RCT Evidence for a Long-Standing Guideline Gray Zone